Junshi Biotech (01877) announced interim results. Profit attributable to shareholders of 25.501 million yuan turned a year-on-year loss into a profit

According to the Zhitong Finance App, Junshi Biotech (01877) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 1,696 billion (same unit), an increase of 45.18% over the previous year; profit attributable to the owners of the Company was 25.501 million yuan, which turned a loss into a profit over the previous year; profit per share was 0.02 yuan.

Among them: (i) Pharmaceutical sales revenue of approximately $1,407 million, an increase of about 33% over the same period in 2025. The increase was mainly due to improved sales efficiency of the commercialization team and approval of more Tuoyi® indications; (ii) revenue related to licensing agreements of approximately $254 million; and (iii) revenue from technical services and other businesses of approximately $35 million.

In the reporting period, Tuoyi®'s domestic sales revenue was approximately $1,299 million, an increase of about 36% over the same period in 2025.